- March 8, 2021
10:00 AM - 2:30 PM ET
On March 8, 2021, FDA hosted a virtual public meeting on Patient-Focused Drug Development for Vitiligo. FDA was interested in hearing patients’ perspectives on the impact of vitiligo on daily life and patient views on treatment approaches.
March 8, 2021
10:00 a.m. - 2:30 p.m. EST
In addition to providing input at the public meeting, stakeholders are invited to provide their perspectives on the discussion questions through the public docket.
- The docket closes on May 10, 2021. FDA is interested in responses to the questions listed in the public docket.
Crowdsourcing is another way for the vitiligo community to engage and interact with each other and the FDA. In addition to the public docket, participants can also submit comments through the crowdsourcing campaign.
Between March 16 and April 2, individuals with vitiligo and their loved ones can log on to the crowdsourcing campaign.
In order to participate in the PFDD Crowdsourcing community, go to http://shareyourvoice.ideascalegov.com/.
- Click “Public Access”
- If you are new to IdeaScale, click “Sign up.” You will be asked to create an account by entering your email address.
- Upon completing the registration process, you will receive a link via email asking you to confirm your email which will activate your account.
- Once you click the link to verify, you will be asked to create a password.
If you have any questions or have trouble accessing the crowdsourcing site, please email ShareYourVoice@fda.hhs.gov.
|Virtual Public Meeting on Patient-Focused Drug Development for Vitiligo||pdf (144.91 KB)|
|Vitiligo PFDD Meeting Slides Final||pdf (1.70 MB)|
|FDA Public Meeting on Patient Focused Drug Development for Vitiligo Transcript||pdf (8.94 MB)|